Adalimumab-induced lichenoid drug eruption

ABSTRACT

Tumor necrosis factor [TNF]- alpha inhibitors are being widely and increasingly used for the management of a spectrum of rheumatologic diseases that are refractory to conventional disease modifying anti-rheumatic drugs. Various cutaneous side effects have been reported after treatment with TNF- alpha inhibitors. We present a case report of a 26-year- old male patient who developed a lichenoid drug eruption few months after the initiation of adalimumab for the manage- ment of Crohn's disease. We also highlight the clinical and histopathologic differences between lichenoid drug eruptions and idiopathic lichen planus